Study guide
9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality
ASCP Hematology Technologist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Hematopoiesis & Cellular Physiology
1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis
2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias
2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias
3 Chapter 3: Hemolytic Anemias & Erythrocytosis
3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification
4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation
4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment
5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms
5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies
6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems
6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia
7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation
7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays
8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics
8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis
9 Chapter 9: Laboratory Operations, Quality Assessment & Safety
9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges
9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality
Key Takeaways Explain This Topic AI
Roughly 60 to 70 percent of laboratory errors are preanalytical; two independent patient identifiers are required and tubes are labeled at the bedside in the patient's presence.
The CLSI order of draw is blood culture, light blue citrate, red/gold serum, green heparin, lavender EDTA, gray fluoride, so that chelating and cationic additives cannot carry over into earlier tubes.
An underfilled EDTA tube shrinks red cells and falsely decreases hematocrit and MCV while raising MCHC; an underfilled citrate tube or a hematocrit above 55% falsely prolongs the PT and APTT and requires citrate volume adjustment.
Delta checks flag physiologically improbable changes whose leading causes are specimen mix-up and dilution from an intravenous line; critical values require direct verbal notification with read-back and full documentation.
The ASCP BOC composite reference ranges are NOT provided during the examination and must be memorized; the coagulation values in that table (PT, APTT, fibrinogen, thrombin time, factor activity) are published for the SH examination only.
Last updated: August 2026
The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality
The ASCP BOC devotes 15 to 20 percent of the H examination to Laboratory Operations, and the first listed sub-topic is quality assessment across the preanalytical, analytical, and postanalytical phases. Roughly 60 to 70 percent of laboratory errors originate before the specimen ever reaches an analyzer, which is why this phase carries the most examination weight.
- 1. The Preanalytical Phase
- Patient and Specimen Identification
Two independent patient identifiers are required (typically full name and date of birth or medical record number); the room number is never an acceptable identifier. Tubes are labeled at the bedside, after collection, in the patient's presence . An unlabeled or mislabeled specimen from an irretrievable source (cerebrospinal fluid, a bone marrow aspirate, an intraoperative specimen) is the one situation in which a recollection is impossible, so a documented re-identification procedure signed by the collector is used instead.
Order of Draw and Additive Carryover
The CLSI order of draw prevents additive carryover between tubes:
- Order Tube Stopper Additive Hematology Relevance
- 1 Blood culture bottle Broth Sterility first
- 2 Light blue 3.2% buffered sodium citrate Coagulation; requires a full 9:1 blood-to-anticoagulant ratio
- 3 Red / gold (SST) None or clot activator plus gel Serum chemistry
4 Green Lithium or sodium heparin Chemistry; unacceptable for smears because heparin gives a blue-grey background on Wright stain
- 5 Lavender K2 or K3 EDTA, 1.5 mg per mL blood CBC, differential, reticulocytes
- 6 Gray Sodium fluoride / potassium oxalate Glucose and lactate
Carryover traps. EDTA drawn before a chemistry tube contaminates it with potassium and chelates calcium and magnesium, falsely raising potassium and lowering calcium. EDTA carryover into a coagulation tube prolongs the PT and APTT.
Fill Volume Errors
Situation Consequence
Underfilled EDTA tube Excess EDTA is hypertonic and shrinks red cells: falsely decreased hematocrit and MCV , increased MCHC, and staining artifact with degenerate leukocytes
Overfilled or inadequately mixed EDTA tube Microclots , producing falsely decreased platelet and leukocyte counts
Underfilled citrate tube Relative citrate excess chelates the calcium added by the reagent, falsely prolonging PT and APTT
Hematocrit above 55% Plasma volume is reduced, so citrate is relatively excessive; the citrate volume must be adjusted: C = ( 1.85 × 10 − 3 ) ( 100 − Hct ) ( V blood ) C = (1.85 \times 10^{-3})(100 - \text{Hct})(V_{\text{blood}}) C = ( 1.85 × 1 0 − 3 ) ( 100 − Hct ) ( V blood )
Common Preanalytical Interferences
Hemolysis (traumatic draw, small-bore needle, vigorous mixing), lipemia, icterus, cold agglutinins, EDTA-dependent platelet clumping, and prolonged tourniquet time causing hemoconcentration. Specimen stability limits matter: EDTA specimens should be analyzed within 24 hours refrigerated , but smears for differential are best made within 4 to 6 hours because storage artifact (vacuolated monocytes, nuclear pyknosis, crenation) accumulates rapidly.
2. The Analytical Phase
The analytical phase begins when the specimen is aspirated. Its quality controls are calibration and calibration verification, daily and interval quality control, instrument maintenance and function checks, reagent lot verification and parallel testing, temperature and equipment monitoring, and documented corrective action. These are covered in detail in the next three sections.
- 3. The Postanalytical Phase
- Result Review, Autoverification, and Delta Checks
Autoverification releases results that fall inside predefined limits without human review; anything outside those rules is held for technologist review. A delta check compares the current result with the same patient's previous result and flags a physiologically improbable change. A hemoglobin that moves from 13.8 to 7.2 g/dL in six hours could be genuine bleeding, dilution from an intravenous line above the draw site, or a specimen mix-up ; the last possibility must be excluded before the result is released.
Critical Value Reporting
Critical values require immediate direct verbal notification to a licensed caregiver with read-back of the patient identifiers and the result , and documentation of the date, exact time, the caller, and the recipient. Representative hematology critical values include hemoglobin below 6.0 g/dL, platelets below 20 x 10^9/L, WBC above 50.0 x 10^9/L or below 0.5 x 10^9/L, new blasts on a smear, positive malaria parasites, an INR above 5.0, and organisms seen in a sterile body fluid.
Corrected Reports and Turnaround Time
A corrected report must retain the original result, clearly identify it as corrected, and record who authorized the change. Turnaround time is monitored from collection (not from receipt) to result availability, since collection-to-receipt delay is itself a common failure point.
4. The ASCP BOC Composite Reference Ranges
The H/SH content guideline publishes a single composite table and states that all corresponding laboratory values on the examination can be interpreted using these ranges . They are not provided during the examination , so they must be memorized. Values appear in both conventional and SI units.
- Analyte Conventional Units SI Units
- RBC 4.00-6.00 x 10^6/uL 4.00-6.00 x 10^12/L
- HGB 12.0-18.0 g/dL 120-180 g/L
- HCT 35-50% 0.35-0.50 L/L
- MCV 76-100 fL 76-100 fL
- MCH 26-34 pg 26-34 pg
- MCHC 32-36 g/dL 320-360 g/L
- RDW 11.5-14.5% 0.115-0.145
- Reticulocytes (absolute) 20-115 x 10^3/uL 20-115 x 10^9/L
- Reticulocytes (relative) 0.5-2.5% 0.005-0.025
- nRBCs 0 per 100 WBC 0 per 100 WBC
- Platelets 150-450 x 10^3/uL 150-450 x 10^9/L
- WBC (total) 3.6-10.6 x 10^3/uL 3.6-10.6 x 10^9/L
- Neutrophils 50-70% (1.7-7.5 x 10^3/uL) 1.7-7.5 x 10^9/L
- Lymphocytes 18-42% (1.0-3.2 x 10^3/uL) 1.0-3.2 x 10^9/L
- Monocytes 2-11% (0.1-1.3 x 10^3/uL) 0.1-1.3 x 10^9/L
- Eosinophils 1-3% (0-0.3 x 10^3/uL) 0-0.3 x 10^9/L
- Basophils 0-2% (0-0.2 x 10^3/uL) 0-0.2 x 10^9/L
- Hgb A / Hgb F / Hgb A2 >95.0% / 0-2.0% / 0-3.5% >0.95 / 0-0.02 / 0-0.035
- CSF WBC and RBC 0-5/uL 0-5 x 10^6/L
- Synovial WBC 0-200/uL, less than 25% PMNs 0-200 x 10^6/L
A distinction worth knowing. The coagulation ranges in that guideline (PT 11.0-14.0 s, APTT 25.0-35.0 s, fibrinogen 160-415 mg/dL, thrombin time 21.0 s or less, factor activity 50-150%) are published for the SH examination only . On the H examination, coagulation reference values are supplied within the question when they are needed, so read each item's stated interval rather than assuming one.